2013 to 2017 Saw Significant Drop in US Melanoma Mortality Rates
The introduction of new melanoma treatments coincided with a reduction in the melanoma mortality rate in the United States.
The introduction of new melanoma treatments coincided with a reduction in the melanoma mortality rate in the United States.
A more than 2-fold increased risk of prostate cancer was seen for patients whose first melanoma diagnosis was 10 to 15 years before study recruitment.
Adjuvant pembrolizumab improved quality of life when compared with ipilimumab or high-dose interferon α 2b.
Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.
Researchers identified a subset of melanoma patients with stage I lesions and negative clinical nodes who had a very low risk of death.
Relatlimab plus nivolumab yields a high pathologic complete response rate in resectable stage III or oligometastatic stage IV melanoma, a phase 2 study suggests.
For patients with melanoma, socioeconomic disparities persist within insured populations, specifically those in nonintegrated health care systems.
Current evidence is insufficient for assessing the balance of benefits and harms of screening for asymptomatic teens and adults.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
Inpatient treatment with immune checkpoint inhibitors is associated with poor survival outcomes in patients with advanced cancer.